Related Experiment Video
Updated: May 4, 2026
08:43
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
Published on: January 31, 2020
6.2K
BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types
Soyoon Ryoo1, Jida Choi2, Jaemyung Kim3
1Laboratory of Cytokine Immunology, Department of Biomedical Sciences and Technology, Konkuk University, Seoul 143-701, Korea. ; Division of Veterinary Bacterial Disease Division, Animal and Plant Quarantine Agency, Gyeonggi-do 480-757, Korea.
Immune Network
|January 4, 2014
Summary
BIRB 796, a p38MAPK inhibitor, reduced inflammatory cytokine IL-8 in THP-1 cells but not Raw 264.7 cells. This suggests the anti-inflammatory drug
Area of Science:
- Immunology
- Pharmacology
- Cell Biology
Background:
- Pro-inflammatory cytokines like TNFα and IL-1β are key in chronic inflammation.
- p38MAPK signaling pathway regulates inflammatory cytokine expression.
- p38MAPK inhibitors are potential anti-inflammatory therapeutics.
Purpose of the Study:
- Investigate the effect of BIRB 796, a p38MAPK inhibitor, on inflammatory cytokine production in various immune cells.
- Determine the cell-type dependency of BIRB 796's anti-inflammatory function.
Main Methods:
- Utilized lipopolysaccharide (LPS) to stimulate immune cells (THP-1 and Raw 264.7).
- Assessed inflammatory cytokine (IL-8) production.
- Analyzed signaling pathway activation using western blot to detect p38MAPK phosphorylation and I-κB degradation.
Main Results:
- BIRB 796 inhibited LPS-induced IL-8 production in THP-1 cells but not in Raw 264.7 cells.
- BIRB 796 effectively suppressed p38MAPK phosphorylation in both cell types.
- BIRB 796 did not prevent I-κB degradation in Raw 264.7 cells.
Conclusions:
- The anti-inflammatory efficacy of BIRB 796 is dependent on the specific immune cell type.
- Differential effects on signaling pathways, such as I-κB degradation, may explain cell-type specific responses.
